Clinical Trial

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Evaluating the Efficacy of Disitamab Vedotin in Combination with RC148 Compared to Albumin-bound Paclitaxone Monotherapy or in Combination with Toripalimab for Subjects with HR-negative, HER2-low Expressing Unresectable Locally Advanced or Metastatic Breast Cancer
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-10-14; most recent amendment 2025-02-14.
Status change: Not Yet Recruiting → Recruiting 2025-01-15
Trial Details
NCT Number NCT06642545
Lead Sponsor RemeGen Co., Ltd.
Conditions Breast Cancer
Enrollment 40 participants
Start Date 2025-02-10
Primary Completion 2026-10-01 (estimated)
Study Completion 2027-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-17